Xiaofu Yu
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA network open
Published: March 27, 2026
A promising model for prediction of chemotherapeutic sensitivity in gastrointestinal cancers using patient-derived malignant ascites organoids.
Journal: Journal of gastrointestinal oncology
Published: February 22, 2025
Immune checkpoint inhibitors plus paclitaxel-based chemotherapy vs. oxaliplatin-based therapy as first-line treatment for patients with HER2-negative unresectable or metastatic gastric/gastroesophageal junction cancer: results of a multicenter retrospective study.
Journal: Translational cancer research
Published: June 27, 2024
Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study.
Journal: Journal of gastrointestinal oncology
Published: September 29, 2023
MPZL1 Promotes Lung Adenocarcinoma Progression by Enhancing Tumor Proliferation, Invasion, Migration, and Suppressing Immune Function via Transforming Growth Factor-β1.
Journal: Human gene therapy
Published: May 15, 2023
Triple‑negative breast cancer cells that survive ionizing radiation exhibit an Axl‑dependent aggressive radioresistant phenotype.
Journal: Experimental and therapeutic medicine
Published: April 13, 2023
A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.
Journal: Journal of cellular and molecular medicine
Published: February 04, 2023
Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.
Journal: Frontiers in oncology
Published: September 28, 2022
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.
Journal: JAMA oncology
Published: August 05, 2021
Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth.
Journal: Nature metabolism
Published: April 21, 2021
WISP3 suppresses ESCC progression by inhibiting the IGF-2-IGF1R-AKT signaling cascade.
Journal: Experimental cell research
Published: April 04, 2021
Last Updated: 09/26/2026